October 25, 2024 8:06am

Realize value should be a mantra with the need of the oversold to flip

Pre-open Indications: 4 Positive and 1 Negative Indications

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441

 

Friday: The pre-open Dow futures are UP +0.21% or (+90 points), the S&P futures are UP +0.28% or (+16 points) and the Nasdaq futures are UP +0.34% or (+70 points)

  • Stock futures rose Friday, following a mixed session close,
  • European stock markets were mixed,
  • Asia-Pacific markets mixed ahead of Japan’s elections.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Thursday: The Dow closed DOWN 140.59- points or -0.33%, the S&P closed UP +12.44 points or +0.21% while the Nasdaq closed UP +138.83 points or +0.76%

Economic Data Docket: more econ …                    

  • 8:30 am                Durable-goods orders                   
  • 8:30 am                Durable-goods minus transportation
  • 10:00 am             Consumer sentiment (final)

 

Tuesday’s RegMed Investors (RMi) Closing bell: “Sector flops while Nasdaq gains. Gloom about the prospect of LPS (loss-per-share) upcoming earnings’ releases also drags on share pricing. Markets also experiences more volatility as election comes closer and economic releases compound. The Harvard Apparatus RT (OTCQB: HRGN) Chronicles: stock drops -$0.42 with 2 shares traded; Ponzi Scheme label is further pronounced and reinforced.” … https://www.regmedinvestors.com/articles/13670   

 

Q43/24: 7 positive and 11 negative closes

Q3/24:

  • September – 10 positive and 10 negative close
  • August – I neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Thursday, Wednesday, Tuesday, Monday, Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed down -$1.18 after Wednesday’s -$1.61. Tuesday’s +$4.47 and Monday’s -$4.22 with a positive +$2.47 or +0.84% aftermarket

Intellia Therapeutics (NTLA) closed down -$4.09 after Wednesday’s -$1.14 with a positive +$0.45 or +2.84% pre-open

Vericel (VCEL) closed up +$0.59 after Wednesday’s +$0.45, Tuesday’s +$0.65 and Monday’s -$0.48 with a positive +$0.85 or +1.98% aftermarket

Voyager Therapeutics (VYGR) closed up +$0.14 after Wednesday’s +0.24 after Tuesday’s -$1.47 with a positive +$0.23 or +3.42% pre-market

 

 Negative Indications:

Thursday, Wednesday, Tuesday, Monday, Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

CRISPR Therapeutics (CRSP) closed up +$1.95 after Wednesday’s -$2.04, Tuesday’s -$0.47 and Monday’s -$0.41 with a negative -$0.10 or +0.21% pre-market

 

 

The BOTTOM LINE: cell and gene therapy sector equities continued its dive from Monday through Thursday as market headwinds drains any share pricing growth

Cell and gene therapy sector equities closed negative on Wednesday, Tuesday and Monday …

  • After last Friday climbed positive having dived on Thursday after positive closes on Wednesday, Tuesday and Monday pushed by a tailwind to a new high
  • After popping on the previous Friday after diving Thursday, Wednesday after Tuesday and Monday negative closes
  • After the previous, previous positive last Friday, diving negative on the previous Thursday, Wednesday and Tuesday - October’s beginning.

 

I am STILL … espousing the cheaper and oversold for … SOME pickups i.e., BUYS!

  • Thursday’s advance/decline line ended with a positive close at the close of 12 incliner, 22 decliners and 1 flat
  • Wednesday’s advance/decline line ended with a negative close at the close of 9 incliner, 23 decliners and 3 flats
  • 10/21 - Tuesday advance/decline line ended with a negative close of 16 incliner, 18 decliners and 1 flat
  • 10/20 - Monday’s advance/decline line ended with a negative close of 4 incliner, 30 decliners and 1 flat

 

As I wrote: “One thought and warning ... If Israel hit/bomb the Iranian oil fields - all market BETS are ... OFF!

 

Although, more weakness could lie ahead with more wild swings like those seen over the past 2 months.

  • Moving forward through October and a few weeks of November, I believe the cell and gene therapy sector equities could be a bit rocky as Q3 LPS (loss-per-share) earnings releases step to bat.
  • I am STILL wondering if … sentiment is moribund.
  • Keep overall exposure low and be ready to exit quickly.
  • As I have joked, “uncle algo and his electronic trading dwarfs” come to roost” until they fly away!

 

Also, the closer we come to the U.S. presidential election; volatility could inject by the VIX (fear gauge) stimulating risk.

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.